ATS 2022
Using Electronic Health Records to Predict Mortality Post COPD Hospitalization
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
Your search for hypertension returned 126 results
ASH 2021
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL
Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.
ASH 2021
Sutimlimab Appears Safe and Efficacious in Patients With Cold Agglutinin Disease
Researchers sought to determine whether sutimlimab would be safe and effective in treating patients with cold agglutinin disease.
ASH 2021
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
ACAAI 2021, News
CHRONICLE Trial Identifies Exacerbation Triggers of Severe Asthma
CHRONICLE investigators reported results of a patient survey on common asthma triggers at ACAAI 2021.
CHEST 2021
Inhaled Treprostinil and Lung Function in Patients With PH-ILD and PAH
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ASCO 2021, News
Daratumumab Maintenance Shows Clinical Benefit in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.
ASCO 2021, News
Carfilzomib-Based Consolidation Regimen May Be Inferior to ASCT in Patients With Multiple Myeloma
Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.
ASCO 2021, News
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
